This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ESMO 2020
ESMO 2020
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Press Releases
ESMO Virtual Congress 2020 Kidney Cancer
Viewing 21-30 of 30 articles
ESMO Virtual Congress 2020: Invited Discussant (LBA26) HIF-2a MK-6482 in Von Hippel-Lindau Disease Associated Cancers and (703M0) Spatial Genomics in Clear Cell RCC Evolution
ESMO Virtual Congress 2020: Invited Discussant LBA26 Oral HIF-2Ī± Inhibitor MK-6482 for Von Hippel-Lindau DiseaseāAssociated ccRCC and 703MO - Spatial Dynamics and Genomic Alterations in Renal Cell Carcinoma
ESMO Virtual Congress 2020: Primary Tumor Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma - Results of the GETUG-AFU 26 NIVOREN Trial
ESMO Virtual Congress 2020: Cabozantinib in Combination with Atezolizumab in Non-Clear Cell Renal Cell Carcinoma: Results from Cohort 10 of the COSMIC-021 Study
ESMO Virtual Congress 2020: An Integrated Study on the Association Between Spatial Dynamics and Genomic Alterations in Renal Cell Carcinoma Evolution
ESMO Virtual Congress 2020: Molecular Profiles and Response Among Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies
ESMO Virtual Congress 2020: An Integrated Study of Spatial Dynamics and Genomic Alterations in Renal Cell Carcinoma Evolution
ESMO Virtual Congress 2020: PD-L1 Prevalence and Association with Clinical Outcomes Among Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies
ESMO Virtual Congress 2020: Treatment-Free Survival, with and without Toxicity, after Immuno-Oncology vs. Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of CheckMate 214
ESMO Virtual Congress 2020: Nivolumab + Ipilimumab vs. Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma in CheckMate 214: 4-Year Follow-up and Subgroup Analysis of Patients without Nephrectomy
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free